Finance

Lists
1099:HKG
Sinopharm Group Co Ltd
15,72 HK$
+0,45%
(+0,070) 1D
16 қаз., 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1099...
Open
15,79 HK$
High
15,99 HK$
Low
15,67 HK$
Mkt. cap
49,06 млрд
Avg. vol.
4,85 млн
Volume
5,89 млн
Dividend
5,03%
Quarterly dividend
0,20 HK$
Ex-dividend date
2026 ж. 23 мау.
P/E ratio
5,90
52-wk high
22,34 HK$
52-wk low
14,55 HK$
EPS
2,67 HK$
Shares outstanding
1,19 млрд
No. of employees
90 мың
Open
15,79 HK$
High
15,99 HK$
Low
15,67 HK$
Mkt. cap
49,06 млрд
Avg. vol.
4,85 млн
Volume
5,89 млн
Dividend
5,03%
Quarterly dividend
0,20 HK$
Ex-dividend date
2026 ж. 23 мау.
P/E ratio
5,90
52-wk high
22,34 HK$
52-wk low
14,55 HK$
EPS
2,67 HK$
Shares outstanding
1,19 млрд
No. of employees
90 мың
News stories
From web sources and news partners
Profile
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical. Its H shares were listed on the Hong Kong Stock Exchange in 2009, with its IPO price of HK$16 per share. Sinopharm Group's subsidiary Sinopharm CNMC and Sinopharm Accord served as the A share counterpart of the company. However, the A share of Sinopharm Group itself was unlisted. Sinopharm Group was ranked 829th in 2016 Forbes Global 2000 list. Wikipedia
About Sinopharm Group Co Ltd
CEO-
Employees90,4 мың
Founded2003
Headquarters-
SectorHealth care provider
Last report
2026 ж. 24 там.
Fiscal period
Q2 2026
- / -
Revenue / Est. (CNY)
142,03 млрд / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in CNY
Loading Previous Earnings...
Revenue
Net income
All values in CNY
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
145,44 млрд
143,69 млрд
140,77 млрд
142,03 млрд
Cost of goods sold
134,52 млрд
133,28 млрд
131,40 млрд
132,33 млрд
Cost of revenue
134,52 млрд
133,28 млрд
131,40 млрд
132,33 млрд
Research and development expenses
172,61 млн
-172,61 млн
46,59 млн
-46,59 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,17 млрд
7,34 млрд
5,10 млрд
5,70 млрд
Operating expense
6,80 млрд
5,00 млрд
6,29 млрд
5,45 млрд
Total operating expenses
141,32 млрд
138,29 млрд
137,69 млрд
137,78 млрд
Operating income
4,12 млрд
5,40 млрд
3,07 млрд
4,26 млрд
Other non operating income
120,78 млн
-427,44 млн
39,60 млн
-100,78 млн
EBT including unusual items
3,67 млрд
3,92 млрд
2,90 млрд
4,05 млрд
EBT excluding unusual items
3,51 млрд
5,36 млрд
2,90 млрд
4,25 млрд
Income tax expense
905,42 млн
1,19 млрд
712,28 млн
1,05 млрд
Effective tax rate
24,66%
30,30%
24,57%
26,02%
Other operating expenses
917,07 млн
-1,10 млрд
204,49 млн
-392,73 млн
Net income
1,84 млрд
1,85 млрд
1,41 млрд
1,99 млрд
Net profit margin
1,27%
1,29%
1,00%
1,40%
Earnings per share
-
-
-
-
Interest and investment income
364,24 млн
-
171,27 млн
-
Interest expense
-412,56 млн
-846,59 млн
-383,82 млн
-505,78 млн
Net interest expenses
-48,32 млн
-846,59 млн
-212,55 млн
-505,78 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
4,66 млрд
5,91 млрд
3,58 млрд
4,78 млрд
Gain or loss from assets sale
11,79 млн
-20,53 млн
-
-14,32 млн
AI content may include mistakes. Learn more
Google қолданбалары